COMP <GO>
SYRE vs JNJ // RETURN ON INVESTED CAPITAL (ROIC)
Spyre Therapeutics Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: SYRE 4
— JNJ 9
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: JNJ
LAST: $96.56 (-2.43%) • MKT CAP: $10.33B
roic
-20.00%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
roic
25.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SYRE VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SYRE | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 44.00% | 67.90% | -23.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -20.00% | 25.50% | -45.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.64% | 2.97% | -4.61 | JNJ | /fcf-yield <GO> |
| Operating Margin | 16.50% | 34.70% | -18.20 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 12.40% | 28.50% | -16.10 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 17.60% | 6.00% | +11.60 | SYRE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.59 | +20.41 | SYRE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 7.20% | -0.70 | SYRE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.1 | 60.4 | -1.29 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.89 | 1.08 | -0.19 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.0x | 23.0x | -1.00 | SYRE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.33B | $662.49B | -$652.16B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SYRE REV | JNJ REV | SYRE GROSS % | JNJ GROSS % | SYRE FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $94.19B | — | 67.9% | -$169.3M | $19.70B |
| FY 2024 | $0 | $88.82B | — | 69.1% | -$157.4M | $19.84B |
| FY 2023 | $886.0K | $85.16B | 44.0% | 44.0% | -$99.9M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SYRE // BETA 0.89
JNJ // BETA 1.08